Mandate

Vinge advises industrifonden in connection with pharmalink’s capital raising of sek 96 million

October 08, 2013

Industrifonden and the Norwegian investment company, Investinor have invested a combined total of SEK 79 million in Pharmalink, the pharmaceuticals development company. Private investors have also contributed to the total capital raising of SEK 96 million. The funds will be used to further develop Pharmalink’s product portfolio.

Pharmalink is a pharmaceuticals company which improves and further develops existing pharmaceuticals. The company is currently conducting the Nefecon project for the treatment of inflammation of the kidneys and the Busulipo project for treatment prior to bone marrow transplantation.

Industrifonden has been a stakeholder in Pharmalink since 2004. The Norwegian investment company, Investinor is a new stakeholder.

Vinge partner Johan Larsson advised Industrifonden

The REPowerEU Plan – The EU Commission’s response to the energy market disruptions

On 18 May 2022, the EU Commission presented the REPowerEU Plan in response to the current world-wide energy market disruptions which have been caused by Russia’s invasion of Ukraine.
May 24, 2022

Sanctions update April 14

Further to our previous sanctions updates Sanctions update March 16, Sanctions Newsletter update 11 of March, Sanctions newsletter of 3 of March, Sanctions newsletter of 25 of February, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
April 14, 2022

New guidance on sustainability agreements between competitors

On 1 March 2022, the European Commission published draft revised guidelines on co-operation between competitors, together with draft revised block exemption regulations for specialisation agreements and R&D agreements. Unlike the current guidelines, which expire on 31 December 2022, the new guidelines include a chapter on the assessment of so-called sustainability agreements.
April 01, 2022